Hepatitis B in India: Systematic review & report of the 'IMA sub-committee on immunization'

Indian Journal of Medical Research

Volumn 127, Issue 5, 2008, Pages 494-497

  Puliyel, Jacob M ^a   Rastogi, Pallav ^a   Mathew, Joseph L ^b  

^a ST STEPHEN S HOSPITAL   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

COCHRANE LIBRARY; DATA ANALYSIS; DEATH; ENDEMIC DISEASE; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INCIDENCE; INDIA; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MEDICAL LITERATURE; PREVENTIVE HEALTH SERVICE; SEROCONVERSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS CARRIER;

CARRIER STATE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INDIA; INFANT; PILOT PROJECTS; VACCINATION;

EID: 51349160123     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Letter

References (43)

1. Dasgupta R, Priya R. The sustainability of hepatitis B immunization within the Universal Immunization Programme in India. Health Policy Plan 2002; 17: 99-105.
2. Raja A. The Minister of State in the Ministry of Health and Family Welfare statement in reply to Rajya Sabha on 12.8.2002; starred question number 408. http://164.100.24.219/rsquestion/ showQn.aspx?qno=71415.
3. Sinha K. Hepatitis B threat eclipses AIDS. Times of India 7.9.2005; New Delhi. http://www.bio-medicine.org/medicine-news/ Hepatitis-B-Vaccine-To-Be-Included-In-National-Immunization- Programme-4777-1, on May 9, 2008.
4. Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Systematic review and meta-analysis of data on point prevalence of hepatitis B in India. Indian Pediatr 2007; 44: 663-75.
5. Schiff ER, Sorrel MF, Maddrey WC. Schiff's Diseases of Liver. Lippincott-Raven Philadelphia 1993.
6. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003; 38: 215-22.
7. Indian Association for Study of the Liver. Hepatitis B in India: Theraputic options and preventive strategies - Consensus Statements. Indian J Gastroenterol 2000; 19 (Suppl 3): C54-74.
8. Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India. IV. Gall bladder and pancreas. Indian J Gastroenterol 1999; 18: 24-8.
9. Miller MA, McCann L. Policy analysis of the use of Hepatitis B, Hemophilius influenzae type B, Streplococcus pneumoniae- conjugate and Rotavirus vaccines in the National Immunization Schedules. Health Econ 2000; 9: 19-35.
10. Miller M. Authors reply. Health Econ 2004; 13: 1147-8.
11. Sarin SK. Hepatitis B leading to hepatocellular carcinoma: calculating the risk. Indian J Gastroenterol 2001; 20: 251-2.
12. Tiwari L, Varghese RM, Puliyel JM. Computerised- hepatitis B -model is subject to processing axiom: garbage in, garbage out. J Hepatol 2003; 39:130-1.
13. Belloni C, Pistorio A, Tinelli C, Komakec J, Chirico G, Rovelli D, et al. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine 2002; 18: 1307-11.
14. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: Comparison of three different vaccination schedules. J Infect Dis 1989; 160: 766-9.
15. Halder SC, Alcada de Monzon M, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indian. Vaccine 1989; 7: 106-10.
16. http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5351-Immunizational.htm/ accessed on April 6, 2007
17. http://www.cispimmunize.org/IZSchedule_Childhood.pdf, Accessed 6/4/ 07
18. Gomber S, Sharma R, Ramchandran VG, Talwar V, Singh B. Immunogenicity of hepatitis B vaccine incorporated into the Expanded Program of Immunization Schedule. Indian Pediatr 2000; 37: 411-3.
19. Akram DS, Maqbool S, Khan DS, Jafri R, Randhawa S, Valenzuela-Silva C, et al. Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children. Vaccine 2005; 23: 5792-7.
20. Andre FE, Safary A. Summary of clinical findings on Engerix- B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J 1987; 63 (Suppl 2): 169-77.
21. Assateerawatt A, Tanphaichitr VS, Suvatte V, Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates,- school children and healthy adults. Asian Pac J Allergy Immunol 1993; 11: 85-91.
22. Bassily S, Kotkat A, Gray G, Hyams KC, Brown FM, Imam IZ, et al. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. Am J Trop Med Hyg 1995; 53: 419-22.
23. Belloni C, Orsolini P, Martinetti M, Chirico G, Cerbo RM, Comolli G, et al. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers. New Microbiol 1993; 16: 237-44
24. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995: 126: 716-21.
25. Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994; 12: 812-8.
26. Moulia-Pelat JP, Spiegel A, Martin PM, Cardines R, Boutin JP, Roux JF, et al. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine 1994; 12: 499-502.
27. Trivello R, Chiaramonte M, Ngatchu T, Baldo V, Majori S, Moschen ME, et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 1995; 13: 139-41.
28. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in north India. J Med Virol 1987; 21: 137-45.
29. Aggarwal R, Naik SR. Prevention of hepatitis B infection: the appropriate strategy for India. Natl Med J India 1994; 7: 216-20.
30. Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003; 23: 309-14.
31. Ni YH, Chang MH, Huang LM Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-800.
32. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001; 139: 349-52.
33. Lin HH, Lin SS, Chiang YM, Wang LY, Huang LC, Huang SC, et al. Trend of hepatitis B virus infection in freshmen classes at two high schools in Hualien, Taiwan from 1991 to 1999. J Med Virol 2002; 67: 472-6.
34. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemol Biomarkers Prev 2003; 12: 57-9.
35. Gong J, Li RQ Yang JY, Li YP, Chen XR, Xu ZY, et al. Long-term efficacy of infant hepatitis B immunization program. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 203-5.
36. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J 2005; 11: 62-7.
37. Da Villa G, Piccinino F, Scolastico C, Fusco M, Piccinino R, Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendernic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol 1998; 149: 263-70.
38. Zanetti AR, Romano L. Evolving epidemiology of viral hepatitis in Italy. Dig Liver Dis 2001; 33: 740-2.
39. Mele A, Stroffolini T, Zanetti AR. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J Med Virol 2002; 67: 440-3.
40. Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunisation as part of the EP1. Vaccine 2000; 19: 943-9.
41. Murhekar MV, Murhekar KM, Das D, Arankalle VA, Sehgal SC, et al. Prevalence of hepatitis B infection among the primitive tribes of Andaman & Nicobar Islands. Indian J Med Res 2000; 111: 199-203.
42. Odusanya OO, Alufohai FE, Meurice FP, Wellens R, Weil J, Ahonkhai VI. Prevalence of hepatitis B surface antigen in vaccinated children and controls in rural Nigeria. Int J Infect Dis 2005; 9: 139-43.
43. Sokhey J, Jain DC, Harit AK, Dhariwal AC. Moderate immunization coverage levels in East Delhi: implications for disease control programmes and introduction of new vaccines. J Trop Pediatr 2001; 47: 199-203.